In this review, the editors will investigate the impact of eight WASH interventions in preventing (reducing the risk of) and controlling outbreaks in LMIC, with particular focus on three diseases of current concern to the response community – cholera, Ebola, and Hepatitis E. Additionally, we will ...explore economic outcomes related to WASH interventions within an outbreak
more
(You need free registration to download the book)
Disasters and public health emergencies can stress health care systems to the breaking point and disrupt delivery of vital medical services. During such crises, hospitals and long-term care facilities may be without power; trained staff, ambulances,... medical supplies and beds could be in short supply; and alternate care facilities may need to be used. Planning for these situations is necessary to provide the best possible health care during a crisis and, if needed, equitably allocate scarce resources
more
DHS Further Analysis Reports No. 100
Report of a WHO technical consultation meeting
Ouagadougou, Burkina Faso
Lancet Glob Health 2015; 3: e396–409. Open Access
Bulletin of the World Health Organization Volume 93, Number 9, September 2015, 589-664
Epidemiologisches Bulletin ; 4/2022
(2015)
Scoping question: Are antidepressants (specifically, tricyclic antidepressants and selective serotonin reuptake inhibitors) effective and safe in adolescents with moderate-severe depressive disorder for whom psychosocial interventions have proven ineffective?
В данном издании представлены результаты оценки системы материнской и неонатальной помощи в Кыргызстане и соответствующие программы. Здесь описана текущая деяте...льность, направленная на улучшение здоровья матери и новорожденного, и инновационные пути для решения существующих трудностей, а также предложена модель проведения оценки эффективности программ, которые созданы на основе доказательной медицины и могут изменить сложившуюся ситуацию.
more
In resource restriced countries
In a retrospective review of hospital records of 40 human monkeypox cases from Nigeria, the majority developed fever and self-limiting vesiculopustular skin eruptions. Five deaths
were reported. Compared to human immunodeficiency virus (HIV)–negative cases, HIV type 1–coinfected cases had more ...prolonged illness, larger lesions, and higher rates of both secondary bacterial skin infections and genital ulcers.
more
En 1998, la Cinquante-et-Unième Assemblée mondiale de la Santé a adopté la résolution
WHA51.11 qui vise l’élimination mondiale du trachome en tant que problème de santé publique
à l’horizon 2020 (1). La stratégie recommandée pour atteindre cet objectif est récapitulée dans
le sig...le « CHANCE » qui signifie CHirurgie pour les personnes atteintes de trichiasis
trachomateux (TT – le dernier stade cécitant du trachome) ; Antibiothérapie, Nettoyage du
visage et Changements Environnementaux (2). Les interventions relatives aux volets A, N et CE
sont menées dans des districts entiers dans lesquels les cas de trachome évolutif
(inflammatoire) sont courants, dans le but de traiter les infections oculaires dues à Chlamydia
trachomatis, l’agent pathogène à l’origine du trachome, et de réduire durablement sa
transmission.
more
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more